Imvax, Inc.

Imvax, Inc. is a US-based biotechnology company focused on developing personalized immunotherapies using whole tumor-derived approaches to enhance the immune response against solid tumors. Founded in 2015, Imvax, Inc. specializes in immunotherapy for solid tumors, headquartered in Philadelphia, US.

Led by CEO John Furey, the company has raised USD 29. 00 mn in venture funding, with its most recent deal on January 29, 2025. The firm has completed five funding rounds to date. Imvax specializes in developing personalized, whole tumor-derived immunotherapies aimed at harnessing the body’s immune response to combat solid tumors.

Their flagship product, developed through the Goldspire® platform, captures the full antigen signature of a patient's tumor, allowing for tailored treatment that stimulates both innate and adaptive immunity against remaining cancer cells. The company has reported promising clinical data for its therapies in glioblastoma and has preclinical advancements in multiple other solid tumors, targeting a diverse pipeline of treatments. Imvax’s solutions are designed for patients diagnosed with solid tumors, primarily in North America and Europe, reflecting a commitment to addressing critical unmet medical needs in oncology. Imvax's revenue structure primarily revolves around B2B partnerships and collaborations with healthcare institutions and research organizations focused on oncology.

The company generates revenue through the sale of its proprietary immunotherapy products, particularly focusing on the flagship Goldspire® platform, which is tailored to individual patients' tumor profiles. Transactions typically involve partnerships with hospitals and clinical research entities that incorporate Imvax’s therapies into their treatment protocols. Revenue is derived from the provision of these specialized treatments, with potential arrangements encompassing service fees, milestone payments, and product sales as part of ongoing clinical trials and therapeutic applications. In January 2025, Imvax, Inc.

raised USD 29. 00 mn in venture funding, which will be utilized to support its Phase 2b Trial of IGV-001. The company plans to launch new immunotherapy products based on advancing its pipeline, targeting broader geographic expansion into Europe and North America by 2026.